Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of investigational MenACWY liquid vaccine versus Menveo in healthy adults
2017-003692-61Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Meningococcal A, C, Y and W-135 conjugate vaccine and meningococcal A conjugate vaccine in meningococcal disease and bacterial meningitis (2 arms), sponsored by GSK. Primary endpoint: hSBA geometric mean titers against Neisseria meningitidis serogroup A. Started Apr 2018; status: completed.
02
Drugs
Meningococcal A, C, Y and W-135 conjugate vaccinemeningococcal A conjugate vaccine
03
Conditions
meningococcal diseasebacterial meningitis
Beyond the preview
Go deeper on 2017-003692-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003692-61.